Related Experiment Videos
[Dyslipidemias and autoimmune diseases]
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
|February 13, 1999
Summary
Dyslipidemias in autoimmune diseases like systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) involve altered cholesterol transport. These changes increase vascular disease risk, necessitating lipid management for better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Clinical Biochemistry
Context:
- Long-term studies (over 30 years) investigating dyslipidemias in autoimmune diseases.
- Antiphospholipid syndrome (APS) has increased focus on lipid metabolism alterations.
- Established link between systemic lupus erythematosus (SLE) and dyslipidemia.
Purpose:
- To summarize findings on blood cholesterol transport system changes in autoimmune diseases.
- To highlight the impact of these dyslipidemias on vascular disease development.
- To emphasize the need for lipid parameter correction in SLE patients.
Summary:
- Patients with SLE exhibit elevated low-density lipoprotein (LDL) cholesterol and reduced high-density lipoprotein (HDL) cholesterol and apolipoprotein A.
- Altered lipoprotein particles impair cholesterol clearance, promoting vascular disease.
- Lipoprotein (a) and oxidized LDL are identified as additional risk factors for thrombosis in SLE and APS.
Impact:
- Corticosteroid use exacerbates lipid profile changes, contributing to atherosclerosis in SLE.
- Correcting blood lipid transport parameters is crucial for preventing vascular disorders.
- Optimizing lipid management improves the overall prognosis for patients with SLE.